Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects
Status:
Completed
Trial end date:
2010-10-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine any differences in pharmacokinetic parameters of
darapladib when dosed to people with moderate liver disease as compared to when dosed in
normal healthy volunteers.